157 related articles for article (PubMed ID: 35487063)
1. Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma.
Kawakami I; Yoshino H; Fukumoto W; Tamai M; Okamura S; Osako Y; Sakaguchi T; Inoguchi S; Matsushita R; Yamada Y; Tatarano S; Nakagawa M; Enokida H
Biochem Biophys Res Commun; 2022 Jun; 611():99-106. PubMed ID: 35487063
[TBL] [Abstract][Full Text] [Related]
2. LncRNA
Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
[TBL] [Abstract][Full Text] [Related]
3. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma.
Liu Y; Yang L; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Sci Rep; 2015 Nov; 5():16954. PubMed ID: 26599282
[TBL] [Abstract][Full Text] [Related]
4. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
5. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.
Hassanein M; Qian J; Hoeksema MD; Wang J; Jacobovitz M; Ji X; Harris FT; Harris BK; Boyd KL; Chen H; Eisenberg R; Massion PP
Int J Cancer; 2015 Oct; 137(7):1587-97. PubMed ID: 25821004
[TBL] [Abstract][Full Text] [Related]
6. Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling.
Liu Y; Wang S; Pan S; Yan Q; Li Y; Zhao Y
J Clin Lab Anal; 2022 Jan; 36(1):e24116. PubMed ID: 34811815
[TBL] [Abstract][Full Text] [Related]
7. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
[TBL] [Abstract][Full Text] [Related]
8. 1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell.
Zhou X; Zheng W; Nagana Gowda GA; Raftery D; Donkin SS; Bequette B; Teegarden D
J Steroid Biochem Mol Biol; 2016 Oct; 163():147-56. PubMed ID: 27154413
[TBL] [Abstract][Full Text] [Related]
9. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
[TBL] [Abstract][Full Text] [Related]
10. TEAD1 (TEA Domain Transcription Factor 1) Promotes Smooth Muscle Cell Proliferation Through Upregulating SLC1A5 (Solute Carrier Family 1 Member 5)-Mediated Glutamine Uptake.
Osman I; He X; Liu J; Dong K; Wen T; Zhang F; Yu L; Hu G; Xin H; Zhang W; Zhou J
Circ Res; 2019 Apr; 124(9):1309-1322. PubMed ID: 30801233
[TBL] [Abstract][Full Text] [Related]
11. Targeting Pulmonary Fibrosis by SLC1A5-Dependent Glutamine Transport Blockade.
Choudhury M; Schaefbauer KJ; Kottom TJ; Yi ES; Tschumperlin DJ; Limper AH
Am J Respir Cell Mol Biol; 2023 Oct; 69(4):441-455. PubMed ID: 37459644
[TBL] [Abstract][Full Text] [Related]
12. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.
Yoo HC; Park SJ; Nam M; Kang J; Kim K; Yeo JH; Kim JK; Heo Y; Lee HS; Lee MY; Lee CW; Kang JS; Kim YH; Lee J; Choi J; Hwang GS; Bang S; Han JM
Cell Metab; 2020 Feb; 31(2):267-283.e12. PubMed ID: 31866442
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism.
Pacifico F; Mellone S; D'Incalci M; Stornaiuolo M; Leonardi A; Crescenzi E
Biochem Pharmacol; 2022 Aug; 202():115159. PubMed ID: 35780827
[TBL] [Abstract][Full Text] [Related]
14. tRF-29-79 regulates lung adenocarcinoma progression through mediating glutamine transporter SLC1A5.
Shi Y; Pan Z; Feng Y; Zhou Q; Wang Q; Wang H; Dong G; Xia W; Jiang F
Carcinogenesis; 2024 Jun; 45(6):409-423. PubMed ID: 38366384
[TBL] [Abstract][Full Text] [Related]
15. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport.
Duan Z; Zhou Z; Lu F; Zhang Y; Guo X; Gui C; Zhang H
Invest New Drugs; 2022 Oct; 40(5):977-989. PubMed ID: 35834041
[TBL] [Abstract][Full Text] [Related]
17. Targeting SLC1A5 blocks cell proliferation through inhibition of mTORC1 in arsenite-treated human uroepithelial cells.
Li S; Zhou Q; Liu W; Fu Z; Zhao H; Xi S
Toxicol Lett; 2021 Jul; 345():1-11. PubMed ID: 33781819
[TBL] [Abstract][Full Text] [Related]
18. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab.
Ma H; Wu Z; Peng J; Li Y; Huang H; Liao Y; Zhou M; Sun L; Huang N; Shi M; Bin J; Liao Y; Rao J; Wang L; Liao W
Int J Cancer; 2018 Jun; 142(12):2578-2588. PubMed ID: 29363109
[TBL] [Abstract][Full Text] [Related]
20. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
